Original Research

Short Interval Repeat Colonoscopy After Inadequate Bowel Preparation Is Low Among Veterans

Author and Disclosure Information

 

References

Based on the identified risk factors, we have created a model for utilizing those risk factors to identify individuals at higher risk for noncompliance (ie, those who live further away from the endoscopy center or currently smoke). These individuals are proactively offered to use an intraprocedural bowel cleansing device to achieve adequate bowel preparation or priority rescheduling for a next-day colonoscopy.

Limitations

This study was a single-center study of the veteran population, which is predominantly White and male, thus limiting generalizability. The study is also limited by minimal available data on adenoma detection and colon cancer incidence on subsequent colonoscopies.

CONCLUSIONS

The rate of IBP was 5.5% in individuals undergoing colonoscopy for colon cancer screening, surveillance, positive FIT, or computed tomography colonography. Only 59.2% of those with IBP underwent the recommended repeat colonoscopy within 1 year. Smoking and distance to the endoscopy center were associated with a decreased adherence to the repeat colonoscopy recommendation. Additional efforts are needed to ensure that individuals with IBP return for timely repeat colonoscopy.

Pages

Recommended Reading

Rare Gems: Navigating Goblet Cell Appendiceal Cancer
Federal Practitioner
Barriers from Detection to Treatment in Lung Cancer: A Single Veteran Affair Institution Review
Federal Practitioner
PHASER Testing Initiative for Patients Newly Diagnosed With a GI Malignancy
Federal Practitioner
How to Make Keeping Up With the Drugs as Easy as Keeping Up With the Kardashians: Implementing a Local Oncology Drug Review Committee
Federal Practitioner
Carboplatin as a Radiosensitizing Agent in Locally Advanced Head and Neck Cancer: Friendly to an Older Veteran Population
Federal Practitioner
The OCTAGON Project: A Novel VA-Based Telehealth Intervention for Oral Chemotherapy Monitoring
Federal Practitioner
CDK7 Inhibition in Patient-Derived Organoid Modeling of Biliary Tract Cancers
Federal Practitioner
Posterior Reversible Encephalopathy Syndrome (PRES) Following Bevacizumab and Atezolizumab Therapy in Hepatocellular Carcinoma (HCC)
Federal Practitioner
VA Cancer Clinical Trials as a Strategy for Increasing Accrual of Racial and Ethnic Underrepresented Groups
Federal Practitioner
Implementation of a Prior Authorization Drug Review Process for Care in the Community Oncology Prescriptions
Federal Practitioner